Same Peptide, Three Supply Chains: What Can the Evidence Actually Prove?
One peptide name can hide very different supply chains. We explain what RUO labels, compounded products and U.S. manufacturing records can tell you, and how our testing helps you ask better questions.
The Letter Is About Copies: What FDA Warning Letter 738238 Actually Says
Most coverage of FDA Warning Letter 738238 to Empower Pharmacy led with sterility. We read the full letter and walk through what it says about compounded copies of approved drugs.
Proof in Public: Why a Live Laboratory Record Changes Verification
Verified by Vanguard gives brands, clinics, quality teams, and customers a direct path to search the issuing laboratory’s public record instead of relying on forwarded screenshots.
The Verification Trap: When the COA Website Is Fake Too
A polished CoA, QR code, padlock, and verification page can still come from one unverified source. Learn how to authenticate a result at the issuing lab.
The Verdict Is In: 70 Months in Federal Prison for Forged Peptide Testing
A landmark federal prosecution exposes the dangers of forged Certificates of Analysis in the research peptide market. What the 70-month prison sentence means for the industry and why independent testing is the only path forward.
Sampling Is Part of the Test: Why the Sample You Send Determines What the Result Means
Even the most accurate lab can only test what you send. How the sample is chosen decides what the result can tell you about the batch.
When the Paper Lies: Exposing Fake CoAs in the Peptide Market
Peptides are now sold over the counter, and some of the certificates of analysis that come with them are forged. How fake COAs work and how to check one.
Why Retatrutide Is the Hardest Peptide to Verify: An Analytical Breakdown
Retatrutide is reaching U.S. buyers before it has been approved. Why it is one of the hardest peptides to verify and what a lab has to check.
The Relabeling Problem: When Your Peptide Vial Lies About Its Origin
Two major legal actions have exposed a massive vulnerability in the peptide supply chain. A Chinese manufacturer on the FDA Green List was caught relabeling semaglutide, and a Utah doctor was indicted for selling relabeled Chinese peptides to 200+ patients.
The “Wild West” Week: What 6 Major Outlets Got Right — and Wrong — About Peptide Quality
Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.